Having trouble accessing articles? Reset your cache.

Leo’s IL-13 mAb hits in atopic dermatitis; how it stacks up against Dupixent remains a question mark

Over a year after the primary completion of tralokinumab’s Phase III studies, Leo Pharma has said the anti-IL-13 mAb met the primary endpoint in all three trials to treat moderate-to-severe atopic

Read the full word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers